Atherosclerosis Supplements
Volume 10, Issue 5 , Pages 85-88, 29 December 2009

Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)

  • U. Kassner

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • Corresponding Author InformationCharité University Clinic Campus Virchow, Interdisciplinary Metabolic Care Centre, Augustenburger Platz 1 13353 Berlin Germany
    • ,
  • A. Vogt

      Affiliations

    • Ludwig-Maximilians-Universität München, Germany
    • ,
  • A. Rosada

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • F. Barz

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • E. Giannakidou-Jordan

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • H.K. Berthold

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany
    • ,
  • E. Steinhagen-Thiessen

      Affiliations

    • Charité Universitätsmedizin Berlin, Germany

Abstract

Lipoprotein(a) (Lp(a)) is a risk factor for premature coronary artery disease. Lp(a) levels can neither be influenced sufficiently by standard hypolipemic diet nor by drug therapy. Currently, lipid apheresis is the only option to effectively lower Lp(a) levels in patients with elevated Lp(a) and progressive CVD. The lipid-clinic at the Charité University hospital Berlin and other German apheresis centres have longstanding positive experience with this therapeutic regimen.

Lately, in Germany lipid apheresis was accepted as the treatment of choice for patients with elevated Lp(a) levels > 60 mg/dl and progres sive CVD. At the same time, care providers were obliged to conduct a controlled trial to prove the efficacy of lipid apheresis for this indication. Therefore, we designed a prospective, randomized, controlled trial to prove the hypothesis that lipid apheresis decreases vascular events.

Keywords:  Lp(a) , Cardiovascular disease , Lipid apheresis

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1567-5688(09)71818-5

doi:10.1016/S1567-5688(09)71818-5

Atherosclerosis Supplements
Volume 10, Issue 5 , Pages 85-88, 29 December 2009

Article Tools